IDEXX Laboratories, Inc.
IDXX
$546.09
-0.88%
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, providing in-clinic analyzers, reference laboratory services, and practice management software for veterinarians, as well as tests for livestock and poultry. The company holds a dominant market position in companion animal diagnostics, differentiated by its integrated platform of instruments, consumables, and data-driven services that enhance clinical efficiency and animal health outcomes. Currently, the stock is under pressure due to a broader market selloff and concerns about post-pandemic normalization in pet healthcare spending, despite the company's recent earnings beat and raised guidance, which highlight resilient demand and operational strength.…
IDXX
IDEXX Laboratories, Inc.
$546.09
Related headlines
IDXX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $698.92 and implied upside of +28.0% versus the current price.
Average Target
$698.92
0 analysts
Implied Upside
+28.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
IDEXX has coverage from 13 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.21 on a scale where 1 is Strong Buy and 5 is Sell). The average price target is $698.92, implying a 26.9% upside from the current price of $550.96, while the low target of $470 suggests a 14.7% downside and the high target of $805 implies a 46.1% upside. The wide spread between low and high targets (from $470 to $805) indicates significant uncertainty about the company's future growth trajectory, with the high target likely assuming continued market share gains and margin expansion, while the low target may reflect concerns about competition or a slowdown in pet spending. Recent ratings have been stable, with no major downgrades, and the last action was UBS reiterating Neutral in April 2026, while Stifel and BTIG maintain Buy ratings, suggesting a generally positive but cautious sentiment.
IDXX Technical Analysis
IDEXX is in a clear downtrend over the past year, with the stock down 15.7% over the last 12 months, significantly underperforming the S&P 500's +20.4% gain. The current price of $550.96 sits at 71.6% of its 52-week range (between $518.55 low and $769.98 high), indicating the stock is closer to its lows than highs, reflecting persistent selling pressure. The 52-week high of $769.98 was set in early 2026, and the stock has since retraced, with a maximum drawdown of -31.3% from that peak, suggesting a bearish trend that has yet to find a definitive bottom.
Beta
1.54
1.54x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$519-$770
Price range past year
Annual Return
-16.1%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | +4.0% |
| 3m | -0.1% | +5.3% |
| 6m | -14.0% | +12.6% |
| 1y | -16.1% | +20.1% |
| ytd | -18.5% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue growth remains robust, with Q1 2026 revenue of $1.14 billion, up 14.3% year-over-year, accelerating from the 9.8% growth seen in Q1 2025. The company has consistently grown revenue over the past eight quarters, from $954 million in Q4 2024 to $1.14 billion in Q1 2026, demonstrating strong demand for its diagnostics. Product revenue of $666 million and service revenue of $475 million in Q1 2026 show a balanced mix, with product sales driving growth due to increased diagnostic frequency and instrument placements.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given IDEXX's positive net income, the trailing P/E ratio of 51.4x is the primary valuation metric, while the forward P/E of 32.9x implies the market expects significant earnings growth. The gap between trailing and forward P/E suggests an anticipated 36% earnings increase over the next year, reflecting optimism about continued margin expansion and revenue growth. The P/E of 51.4x is at a 134% premium to the industry average of 22x, indicating the market is pricing in superior growth and profitability, which is justified by IDEXX's 24.6% net margin and 31.6% operating margin, both well above industry norms.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple